Screener
Eli Lilly LLY Reportable Segment — Acquired in-process research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Early-stage research and development(1) | 1,450 | 1,156 | 2,715 | 2,146 |
| Late-stage research and development(1) | 2,368 | 2,180 | 4,613 | 3,924 |
| Marketing, selling, and administrative | 3,430 | 2,753 | 6,364 | 5,221 |
| Acquired in-process research and development | 2,776 | 154 | 3,360 | 1,726 |
| Other segment items(2) | 2,587 | 1,207 | 4,384 | 2,177 |
| Net income | $7,095 | $5,661 | $14,491 | $8,420 |
| Interest expense | $345 | $249 | $677 | $493 |
| Expenditures for long-lived assets(3) | 2,906 | 1,985 | 5,344 | 3,502 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's reportable segment — acquired in-process research and development?
- Eli Lilly (LLY) reported reportable segment — acquired in-process research and development of $2.78B in Q2 2026.
- How has Eli Lilly's reportable segment — acquired in-process research and development changed year-over-year?
- Eli Lilly's reportable segment — acquired in-process research and development increased by 1702.6% year-over-year, from $154M to $2.78B.
- What is the long-term trend for Eli Lilly's reportable segment — acquired in-process research and development?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — acquired in-process research and development has grown at a 47.4% compound annual growth rate (CAGR), from $908.5M to $2.91B.
- What does reportable segment — acquired in-process research and development mean?
- Reflects the costs associated with acquiring intellectual property or research projects from third parties that have not yet reached regulatory approval. This represents the segment's strategy to bolster its future pipeline through external innovation rather than purely internal development. It is a key indicator of long-term growth investment and capital allocation strategy.
Ask your AI about Eli Lilly's reportable segment — acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude